50865.1 IP-LS

Résumé

Translational IND enabling studies to develop an innovative drug candidate, TOP-V122 for the treatment and prevention of colorectal cancer.

Textes supplémentaires

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer death and the third most prevalent cancer worldwide. Survival rate at a later diagnosis is 13.5%. With our approach, based on a unique mode of action drug that restore cGMP levels, we aim to treat CRC and to increase the survival rate.

Participants

Michael Scharl

Kontaktperson

michael.scharl@usz.ch

USZ Universitätsspital Zürich Division of Gastroenterology and He Michael Scharl Rämistrasse 100 8091 Zürich ZH CH

Rita De Brito Francisco

Wirtschaftspartner

Topadur Pharma AG CHE-481.951.668 Rita De Brito Francisco Grabenstrasse 11a 8952 Schlieren ZH CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2021-04-30
Date de fin: 2023-08-31
Coûts totaux approuvés: CHF 859271.00
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

T410 Pharmaceuticals and related technologies 100.0%